Expert Opinion on Investigational Drugs, 26(11), 12891296
Eco-friendly packaging - 100% biodegradable packaging made from plant-based materials
At clinical doses, the peptide activates collagen synthesis, accelerates cell turnover, and modulates the inflammatory response across multiple tissue types
In contrast to Ffar1 deletion, overnight culture induced pronounced changes, i.e
IGF-1 DESs short half-life makes it ideal for: Targeted injection into desired muscle groups Minimizing risk of systemic IGF-1 overexposure (which can lead to unwanted growth in non-target tissues) How It Differs From IGF-1 LR3 The DES(1-3) form of IGF-1 demonstrates higher potency for local anabolic effects due to enhanced receptor affinity and reduced binding to IGF binding proteins. Philippou et al., Cell Communication and Signaling Clinical & Performance Use Today While IGF-1 DES remains a research peptide and is not FDA-approved for human therapeutic use, it is widely used off-label by: Bodybuilders targeting lagging muscle groups (arms, calves, chest) Strength athletes recovering from tendon and ligament injuries Physique competitors preparing for contests Anti-aging practitioners promoting collagen synthesis and joint health It is also commonly stacked with: GH secretagogues (MK-677, CJC-1295, Ipamorelin) Recovery peptides (BPC-157 for Recovery, TB500) for comprehensive muscle growth + tissue repair protocols
